

## Novel Results on the Biocyclisation of 2,3-Oxidosqualene Analogs by Sterol Cyclase


Alain Krief \*\*, Patrick Pasau, \* Eric Guittet, # Yang Yin Shan # and Marc Herin. §

\* Department of Chemistry, Facultés Universitaires Notre-Dame de la Paix, 61 rue de Bruxelles  
 B-5000, Namur (Belgium). # Laboratoire de RMN, Institut de Chimie des Substances Naturelles du CNRS,  
 Gif sur Yvette, F-91190 (France). § Searle European Development Center, Mont-Saint Guibert, (Belgium).

(Received in USA 8 October 1992)

*Although Oxidosqualenes analogs bearing a E- $\Delta^{18-19}$  C,C double bond are cyclized by 2,3-oxidosqualene cyclase (EC 5.4.99.7, "sterol cyclase") to produce 20-R norlanosterols, thoses possessing a Z- $\Delta^{18-19}$  C,C double bond instead produce, a mixture of 20-S norlanosterols and tricyclic derivatives whose ratio depends upon the length of the side chain.*

A few years ago we reported that 2,3-oxidosqualene analogs possessing a Z- $\Delta^{18-19}$  C,C double bond **1a<sub>Z</sub>**<sup>1</sup> and **1b<sub>Z</sub>**<sup>2</sup> are cyclized by 2,3-oxidosqualene cyclase (EC 5.4.99.7, "sterol cyclase") to produce inter alia a tetracyclic compound with norlanosterol structure, **2a<sub>S</sub>**, but inverted stereochemistry at C-20, or tricyclic derivatives **3b<sub>Z</sub>** or **4b<sub>Z</sub>**, depending upon the length of the chain attached at C-19 of **1<sub>Z</sub>** (Scheme 1 and 2). These clear cut results led us to investigate the behavior of **1c<sub>Z</sub>** possessing the same stereochemistry but an alkyl side chain with intermediate structure between the one of **1a<sub>Z</sub>** and **1b<sub>Z</sub>** and to determine the structure of some minor compounds isolated in our previous work.<sup>1,2</sup>



The (±) 2,3-oxidosqualene analog **1c<sub>Z</sub>** (302 dpm/nmol.) was synthesized<sup>3,4</sup> as described below and incubated with a purified preparation of 2,3-oxidosqualene cyclase from pig liver<sup>5</sup> (5 mg, 0.12 mmol., 3905292 dpm, 6 ml AII fraction, 20°C, 3h, under nitrogen). The resulting mixture was saponified, extracted with ether and purified on SiO<sub>2</sub> (preparative TLC plate, Merck, benzene-ethyl acetate 95-5) yielding recovered **1c<sub>Z</sub>** (70%, R<sub>f</sub> 0.8), an intractable mixture of **2c<sub>S</sub>** and **5c<sub>Z</sub>** (ratio 40/60, R<sub>f</sub> 0.45-0.34) and **3c<sub>Z</sub>** (R<sub>f</sub> 0.20-0.14) each mixed with unlabeled compounds present in the enzymic preparation.<sup>6-8</sup>

**2c<sub>S</sub>** and **5c<sub>Z</sub>** were in turn separated as their acetates **2c<sub>S</sub>-Ac** and **5c<sub>Z</sub>-Ac** by sequential acetylation (excess Ac<sub>2</sub>O, pyridine, 20°C, 17h, 93% yield) followed by HPLC purification (Lichrosorb, RP-18, 7μ, Merck, methanol) and have been obtained free from unlabeled compounds. **3c<sub>Z</sub>** was further freed from the high amount of exogenous cholesterol present by crystallization followed by HPLC purification (Lichrospher, Si-100, 5μ, Merck, hexane-ether 8-2). The structures of **2c<sub>S</sub>-Ac**, **3c<sub>Z</sub>** and **5c<sub>Z</sub>-Ac** were determined by <sup>1</sup>H, <sup>13</sup>C 1D and 2D NMR. Spectra (DQF-COSY, NOESY, Long range COSY, HMQC) of **3c<sub>Z</sub>**<sup>9,10</sup> were compared

with those of its related derivative **3b<sub>Z</sub>**<sup>9,10</sup> and spectra of **2c<sub>S</sub>-Ac** were compared with those of an authentic sample.<sup>11,12</sup>

The presence of the tricyclic product **5c<sub>Z</sub>** as the major cyclized component from the biotransformation involving **1c<sub>Z</sub>** led us to suspect the presence of related derivatives among the various products isolated in small quantities in the reactions involving **1a<sub>Z</sub>** and **1b<sub>Z</sub>**.<sup>1,2</sup> We therefore repeated both biosynthetic experiments, and in doing so confirmed our previous results and isolated one compound in each case to which we have assigned the structure **5a<sub>Z</sub>** (12% yield) and **5b<sub>Z</sub>** (1.4% yield). We recall that such tricyclic products have also been isolated in the biocyclization of 2,3-oxidosqualene analogs **1a<sub>E</sub>** possessing a E  $\Delta^{18-19}$  C,C double bond and **1d**.<sup>13</sup>

Scheme 2

Entry		Yield in 2	Yield in 3	Yield in 4	Yield in 5
a	R = H	62% (2d)	0% (3d)	0% (4d)	10% (5d)
b	R = Me	46% (2a)	0% (3a)	0% (4a)	13% (5a)
c	R = Et	16% (2c)	12% (3c)	0% (4c)	26% (5c)
d	R =	0% (2b)	38% (3b)	20% (4b)	1.4% (5b)

The results of our work involving the reaction of four 2,3-oxidosqualene analogues **1<sub>Z</sub>** possessing a Z  $\Delta^{18-19}$  C,C double bond bearing a side chain of different length are assembled in scheme 2. Particularly impressive is the fact that all of these unnatural substrates are so well accepted and cyclized by 2,3-oxidosqualene cyclase from pig liver (EC 5.4.99.7, "sterol cyclase", **1a<sub>Z</sub>-c<sub>Z</sub>,d**: 80, 78, 60 and 76% yields).<sup>14</sup> It can be observed that the shorter the side chain (i.e. the smallest the modification is compared to the natural substrate) the higher the percentage of 20(S)-lanosterol analogue **2** formed and the lower the amount of the tricyclic derivatives **3<sub>Z</sub>**, **4<sub>Z</sub>** and **5<sub>Z</sub>** produced. It is nevertheless difficult to rationalize the ratios of the different tricyclic derivatives formed. Why **4<sub>Z</sub>** is so scarcely produced and why the percentage of the tricyclic products **5<sub>Z</sub>** is so fluctuating is unclear. The fact that only one of the possible stereoisomers of **5<sub>Z</sub>** is produced in each case suggests that they are each formed in a biosynthetic step and do not result, for example, from **3<sub>Z</sub>** or **4<sub>Z</sub>** via an acid catalyzed non enzymic pathway.<sup>15</sup>

The stereochemistry of the tricyclic skeleton in **3<sub>Z</sub>** and **4<sub>Z</sub>** and the  $\beta$ -orientation of their side chains suggest that the cyclization takes place through anti-periplanar additions of the C,C double bonds of the 2,3-oxidopolyenes folded in the enzyme in a chair-boat-chair conformation. The case of the tricyclic product **5<sub>Z</sub>** is more intriguing since again the side chain is  $\beta$ -oriented. This can be rationalized by considering that **5<sub>Z</sub>** is derived: (i) from a tricyclic skeleton bearing an  $\alpha$ -oriented side chain and arising from anti-periplanar addition of C,C double bonds of 2,3-oxidopolyenes folded in the enzyme in a chair-boat-boat conformation. The (H, Me) migrations and the loss of the hydride which led finally to the olefinic compound **5<sub>Z</sub>** are therefore expected to occur through concerted anti-periplanar 1,2-shifts, (ii) from the precursors of **3<sub>Z</sub>** and/or **4<sub>Z</sub>** bearing a  $\beta$ -oriented side chain arising from the 2,3-oxidopolyenes folded in the enzyme in a chair-boat-chair conformation. In order to explain the  $\beta$ -orientation of the side chain in **5<sub>Z</sub>**, we must assume, that a stepwise mechanism is operative involving a syn-periplanar migration of at least the first migrating Me group.<sup>16,17</sup> In

order to fully understand the intimate mechanism of transformation of **1<sub>Z</sub>** to **3<sub>Z</sub>**, **4<sub>Z</sub>** and **5<sub>Z</sub>** it is important to determine unambiguously the stereochemistry at the remaining chiral center on the side chain of these compounds. We are currently working towards this end.


The authors thanks IRSIA (Institut pour l'Encouragement de la Recherche dans l'Industrie et l'Agriculture, Belgium for a fellowship to one of us (P.P.)

#### References

1. Hérin, M.; Sandra P.; Krief, A. *Tetrahedron Lett.* **1979**, 3103.
2. Krief, A.; Schauder, J.-R.; Guittet, E.; du Penhoat, C.H.; Lallemand, J.-Y. *J. Amer. Chem. Soc.* **1987**, *109*, 7910.
3. The 2,3-oxidosqualene **1c<sub>Z</sub>** and **1c<sub>E</sub>** possessing a Z or a E  $\Delta^{18-19}$  C,C bond were synthesized as shown in scheme 3, using the Biellmann coupling reaction, between the functionalized  $\alpha$ -lithio allylic sulfide **2** **6c** and the allylic chlorides **12**. The latter were in turn prepared by a sequence of reactions which involved (i) the ozonolysis of geranyl benzyl ether [(a) 1.3 equiv. O<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, -78°C (b) Me<sub>2</sub>S, 40°C, 2h, then 25°C, 12h, 60% yield in **7c**] and (ii) its further reaction with 2-lithio-2-methylseleno pentane **8** **4** [(a) 1.3 equiv., THF, -78°C, 1h (b) aq. NH<sub>4</sub>Cl, 20°C, 77% yield in **9** as a 1/1 mixture of diastereoisomers **9c<sub>Z</sub>** and **9c<sub>E</sub>**]. This mixture was resolved in its constituents by chromatography on silicagel [Lobar, Lichroprep Si, Merck] eluted with a solution of hexane-ethyl acetate: 96-4, TLC (SiO<sub>2</sub>, pentane-ether 80-20, four elutions, **9c<sub>Z</sub>**: 35% yield, R<sub>f</sub> 0.73; **9c<sub>E</sub>**: 27% yield, R<sub>f</sub> 0.67]. Purified **9c<sub>Z</sub>** and **9c<sub>E</sub>** were in turn reacted with PI<sub>3</sub> [1.5 equiv., 9 equiv. NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 20°C, 1h] stereospecifically producing the 2E,6Z **10c<sub>Z</sub>** and the 2E,6E **10c<sub>E</sub>** 1-benzyloxy-3,7-dimethyl decadiene in 88 and 86% yields respectively [TLC, SiO<sub>2</sub>, pentane-ether 94-6, **10c<sub>Z</sub>** R<sub>f</sub> 0.76 and **10c<sub>E</sub>** R<sub>f</sub> 0.75]. Deprotection of the benzyl ethers led to the corresponding alcohols [3.7 equiv. Li, ether-NH<sub>3</sub>: 1-2.3, -78°C, 0.3h then i-PrOH then NH<sub>4</sub>Cl, **11c<sub>Z</sub>** or **11c<sub>E</sub>**: 95% yield, R<sub>f</sub> 0.53 each, TLC, SiO<sub>2</sub>, pentane-ether 60-40] which were in turn transformed to the corresponding E-allylic chlorides **12** by the Stork-Grieco method [(a) 1 equiv. MeLi, ether-HMPA: 2-1, 0°C (b) 1.5 equiv. TosCl, 20°C, 7 equiv. LiCl, 20°C, 15h, 99% yield each]. The synthesis of **1c** was achieved from that stage by (i) alkylation of **6c** [from the corresponding sulfide (a) 0.9 equiv. n-Buli, THF, -78°C, 2.5h and (b) 0.7 equiv. **12**, THF, -78°C, 2h, **13c<sub>Z</sub>**: 60% yield, **13c<sub>E</sub>**: 70% yield, R<sub>f</sub> 0.6 each, TLC, SiO<sub>2</sub>, pentane-ether 94-6] and (ii) further reduction of the resulting sulfide [30 equiv. Li, EtNH<sub>2</sub>, -15°C, 0.5h then NH<sub>4</sub>Cl, **14c<sub>Z</sub>** or **14c<sub>E</sub>**: 67% yield and R<sub>f</sub> 0.86 each, TLC, SiO<sub>2</sub>, pentane-ether 94-6]. The dioxolane moiety in **14c** was removed by treatment with aqueous lithium perchlorate to provide the diols **15c** [3N, aq. HClO<sub>4</sub>, THF, 20°C, 5h, **15c<sub>Z</sub>** or **15c<sub>E</sub>**: 90% yield and R<sub>f</sub> 0.8 each, TLC, SiO<sub>2</sub>, pentane-ether 30-70] which were immediately cyclized to **1c** through their mesylates [(a) 10 equiv. MeSO<sub>2</sub>Cl, pyridine, 20°C, 3h (b) K<sub>2</sub>CO<sub>3</sub>, MeOH, 20°C, 2h, **1c<sub>Z</sub>** or **1c<sub>E</sub>**: 86% yield from **15** and R<sub>f</sub> 0.48 each, TLC, SiO<sub>2</sub>, benzene). Tritiated **1c<sub>Z</sub>** or **1c<sub>E</sub>** were obtained from **15c<sub>Z</sub>** and **15c<sub>E</sub>** by their sequential cleavage to the aldehydes **16c** (NaIO<sub>4</sub>, MeOH, phosphate buffer pH 7.2, 0°C, 1h, 0°C, 3h, **16c<sub>Z</sub>**: 80% and **16c<sub>E</sub>**: 90% yield and R<sub>f</sub> 0.76 each, TLC, SiO<sub>2</sub>, benzene) followed by their tritiation [(1Ci/ml) T<sub>2</sub>O, NEt<sub>3</sub>, THF, 50°C, 17h, sealed tube, quantitative yield, **16c<sub>Z</sub>**\*: 6036 and **16c<sub>E</sub>**\*: 3398 dpm/nmole) and their further reaction with isopropylidene diphenylsulfurane [(a) Ph<sub>2</sub>S-CHMe<sub>2</sub>, BF<sub>4</sub>, 1 equiv. LDA, 1 equiv. CH<sub>2</sub>Cl<sub>2</sub>, -78°C, 0.5h, THF, then addition of **16c**\*, -78°C, 3h, **1c<sub>Z</sub>**\* 50% yield and **1c<sub>E</sub>**\* 54% yield].
4. (a) Krief, A.; Dumont, W.; Cravador, A.; Denis, J.N.; Halazy, S.; Hevesi, L.; Labar, D.; Lucchetti, J.; Rémon, J.; Sevrin, M.; Van Ende, D. *Bull. Soc. Chim. Fr.*, **1980**, N° 11-12, II, 519 (b) Labar, D.; Krief, A. *J. Chem. Soc. Chem. Commun.*, **1982**, 564 and references cited. (c) Krief, A. *Comprehensive Organic Synthesis*, Trost, B.M.; Fleming, I.; Schreiber, S. ed. **1992**, vol 1, Ch. 2.6, 629.
5. Yamamoto, S.; Lin, K.; Bloch, K. *Proc. Natl. Acad. Sci. USA*, **1969**, 63, 110
6. Unidentified compounds (a) 1% (b) 3% (R<sub>f</sub> 0.05) are also present in this mixture.
7. For the purpose of comparison, we investigated the behavior of the stereoisomeric 2,3-oxidosqualene **1c<sub>E</sub>** possessing a E- $\Delta^{18-19}$  C,C bond and observed that it led exclusively to the formation of the 20(R)-norlanosterol derivative **2c<sub>R</sub>**.<sup>8</sup>
8. This compound was compared with an authentic sample prepared (scheme 4) from lanosteryl acetate via ozonolysis of its 24-25 C,C double bond, Wolf-Kishner reduction of the resulting aldehyde **17** [(i) (a) O<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>-pyridine, 0°C, 64% yield (b) 2.8 equiv. Me<sub>2</sub>S, 20°C, 3h (ii) NH<sub>2</sub>NH<sub>2</sub>, KOH, ethylene glycol-ethanol, 120°C, 1h, 180°C, 2h, 200°C, 0.2h, quantitative yield in **2c<sub>R</sub>**, 96% purity].
9. The 2D NMR spectra of **3c<sub>Z</sub>**, which is for obvious reasons simpler than that of **3b<sub>Z</sub>** shows that the side chain on the five membered ring lies on the  $\beta$ -side. Comparison of both spectra clearly suggested a

- similar orientation for the side chain on **3b<sub>Z</sub>** and on the basis of additional experiments (NOESY at 600 MHz among others) we have reassigned <sup>10</sup> its stereochemistry at that center.
- Guittet, E.; du Penhoat, C. H.; Lallemand, J.-Y.; Schauder, J.-R.; Krief, A. *J. Amer. Chem. Soc.*, **1987**, *109*, 7911.
  - Prepared from  $\beta$ -tetrahydropyranyloxy lanosterol by a sequence of reactions which involved the intermediary formation of **18**,<sup>12</sup> its further reaction with ethyl magnesiumbromide [2.9 equiv., ether-benzene 3-1, 25°C, 1h, 88% yield, contaminated with 5% of its 20R stereoisomer] leading to the alcohol **19** which after oxidation and removal of the THP group produces **20** [(i) 6.3 equiv. PCC, 4.2 equiv. AcONa, CH<sub>2</sub>Cl<sub>2</sub>, 20°C, 3.5h (ii) 0.5 equiv. PTSA, MeOH-CH<sub>2</sub>Cl<sub>2</sub> 2-1, 20°C, 3h, 74% overall yield]. The latter was in turn transformed to the desired norlanosterol **2c<sub>S</sub>** by reduction of the corresponding thioacetal **21** [(i) (CH<sub>2</sub>SH)<sub>2</sub>, AcOH, Et<sub>2</sub>O-BF<sub>3</sub>, 20°C, 24h, 86% yield (ii) Li, EtNH<sub>2</sub>, -15°C, 0.25h, 92% yield including 19% of another compound to which we have not attributed a structure and which was separated from the desired compound after acetylation.
  - Schauder, J.R.; Krief, A. *Tetrahedron Lett.* **1982**, *23*, 4389.
  - Krief, A.; Pasau, P.; Quéré, L. *Biorg. & Med. Chem. Lett.* **1991**, *1*, 365.
  - This is not the case if *Saccharomyces cerevisiae* is used instead.<sup>13</sup>
  - We have observed during a <sup>1</sup>H NMR experiment performed in impure CDCl<sub>3</sub> containing a trace of acid, that **3c<sub>Z</sub>** led (trace of HCl, CHCl<sub>3</sub>, 20°C) to **4c<sub>Z</sub>** (life time < 0.1h) which immediately rearranged to a large number of "by-products" containing traces of **5c<sub>Z</sub>**. We have ruled out a chemical isomerisation of **3c<sub>Z</sub>** to **5c<sub>Z</sub>** since we have not found such "by-products" besides **5c<sub>Z</sub>** in the biosynthetic experiment and because we recovered **3c<sub>Z</sub>** and not **5c<sub>Z</sub>** when a pure sample of **3c<sub>Z</sub>** was purified again under the same conditions used for its former purification.
  - This kind of assumption has been also used by Corey<sup>17</sup> to explain the stereochemistry of the  $\beta$ -oriented side chain at C-17 of a protosterol derivative occurring from cyclisation of an oxidosqualene analogue bearing a  $\Delta^{20-21}$  extra C,C double bond.
  - Corey, E.J.; Virgil, S.C.; Sarshar S. *J. Amer. Chem. Soc.*, **1991**, *113*, 8171.

Scheme 3\*



\* Series a: R<sub>1</sub>=Me, R<sub>2</sub>=Pr, Series b: R<sub>1</sub>=Pr, R<sub>2</sub>=Me

Scheme 4

